FDA advisory panel votes in favour of Replimune's oncolytic virus melanoma treatment RP1

An FDA advisory committee voted in favour of Replimune's investigational melanoma treatment RP1, known generically as vusolimogene oderparepvec, according to live coverage published by Stat News on 30 July 2026. RP1 is an engineered oncolytic herpes simplex virus designed to selectively replicate within tumour cells, inducing direct cell lysis and stimulating a systemic anti-tumour immune response. It is intended for use in patients with advanced melanoma.

Advisory committee votes are not regulatory approvals; the FDA is not bound by committee recommendations, though it frequently takes them into account when making final licensing decisions. The committee's endorsement follows a phase II trial programme; Stat News notes the session was live-blogged, suggesting the vote was not unanimous or straightforward, though the outcome was positive for the sponsor.

RP1 is distinct from earlier oncolytic virus therapies such as talimogene laherparepvec (T-VEC), which is already approved for melanoma. Whether the committee viewed RP1 as offering a clinically meaningful advance over existing options is not detailed in the lede material available, and the full discussion will be reflected in the official meeting transcript.

For oncologists and researchers following the hereditary melanoma and somatic melanoma genomics space, regulatory progress for novel immunotherapy agents is relevant context. The FDA is expected to make a final decision within its standard review timeline.